Prophylactic platelet transfusions in patients with haematological malignancies – lessons from the TOPPS trial
People with haematological malignancies are the largest patient group who use platelet components, and platelet transfusions are an important supportive therapy during treatment with chemotherapy or haematopoietic stem cell transplantation (HSCT).
| 第一著者: | |
|---|---|
| フォーマット: | Conference item |
| 出版事項: |
Wiley
2016
|